Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed.
Inactivation of ornithine aminotransferase by (1Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Koon Mook KangDepartment of Chemistry, Northwestern University, Evanston, Illinois 60208, United States.ORCID 0000-0001-9336-840X
Abigail L VargasDepartment of Chemistry and Biochemistry, Loyola University Chicago, Chicago, Illinois 60660, United States.
Luana Assis FerreiraDepartment of Psychological and Brain Sciences, Indiana University, Bloomington, Indiana 47405, United States.
Benjamin James Des SoyeDepartment of Chemistry, Northwestern University, Evanston, Illinois 60208, United States.ORCID 0000-0001-5480-4192
Mary CorriganDepartment of Chemistry and Biochemistry, Loyola University Chicago, Chicago, Illinois 60660, United States.
Cathy Kexin ZhangDepartment of Chemistry, Northwestern University, Evanston, Illinois 60208, United States.ORCID 0000-0002-7942-6850
Feng WangDepartment of Chemistry, Northwestern University, Evanston, Illinois 60208, United States.
Dorothy DuanDepartment of Chemistry, Northwestern University, Evanston, Illinois 60208, United States.
Neil L KelleherDepartment of Chemistry, Northwestern University, Evanston, Illinois 60208, United States.ORCID 0000-0002-8815-3372
Andrea G HohmannDepartment of Psychological and Brain Sciences, Indiana University, Bloomington, Indiana 47405, United States.
Dali LiuDepartment of Chemistry and Biochemistry, Loyola University Chicago, Chicago, Illinois 60660, United States.ORCID 0000-0002-7587-703X
Richard B SilvermanDepartment of Chemistry, Northwestern University, Evanston, Illinois 60208, United States.ORCID 0000-0001-9034-1084
Funding
The UIUC Neuroproteomics Center on Cell-Cell SignalingP30DA018310 · NIDA · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI Jonathan V. Sweedler · 2004 to 2026
$24.9M
TR&D 7: Cell Specific ProteomicsP41GM108569 · NIGMS · NORTHWESTERN UNIVERSITY · PI KELLEHER, NEIL L · 2015 to 2024
$13.6M
New Inactivators of GABA Aminotransferase for Addiction and EpilepsyR01DA030604 · NIDA · NORTHWESTERN UNIVERSITY · PI SILVERMAN, RICHARD B · 2011 to 2020
$4.0M
National Center for Translational and Developmental ProteomicsRM1GM156535 · NIGMS · NORTHWESTERN UNIVERSITY · PI NEIL L KELLEHER · 2025 to 2026
$3.4M
CB2 Cannabinoid Mechanisms for Suppressing Opioid Tolerance and DependenceR01DA047858 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI HOHMANN, ANDREA GRACE, MACKIE, KENNETH · 2019 to 2023
$2.6M
New Inactivators of GABA Aminotransferase for Epilepsy and Neuropathic PainR01NS123057 · NINDS · NORTHWESTERN UNIVERSITY · PI SILVERMAN, RICHARD B · 2021 to 2025
$2.5M
Ornithine Aminotransferase Inactivation, a New Approach for Treatment of CancersR01CA260250 · NCI · NORTHWESTERN UNIVERSITY · PI RICHARD B SILVERMAN · 2021 to 2026
$2.3M
STRUCTURAL BIOL RES: LUNG SURFACTANT PROTEINS, DISTRESSS10RR019071 · NCRR · NORTHWESTERN UNIVERSITY · PI RADHAKRISHNAN, ISHWAR · 2005 to 2005
$272k
600 MHz NMR Instrument Upgrade at Northwestern UniversityS10OD012016 · OD · NORTHWESTERN UNIVERSITY · PI RADHAKRISHNAN, ISHWAR · 2012 to 2012
Currently, mechanism-based inactivators (MBIs) are the only available therapeutic option to target γ-aminobutyric acid aminotransferase (GABA-AT). However, off-target activity against homologous enzymes is a well-recognized challenge for the clinical use of MBIs. For example, CPP-115, an MBI of GABA-AT that completed a Phase I clinical trial, also inactivates ornithine aminotransferase (OAT). Here, we present a comprehensive investigation of an OAT-specific inactivation mechanism for CPP-115 by integrating biochemical experiments, X-ray crystallography, and computational simulations. Unlike in GABA-AT, where CPP-115 forms a noncovalent tight-binding adduct only, a covalent adduct was additionally observed with human OAT (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Targeting Conformational Flexibility of a Reactive Intermediate to Enhance Selectivity of a GABA Aminotransferase Inactivator. · full record | OpenQuestion